It is made available under a CC-BY 4.0 International license .

# 1 Original article

Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19
among first, second, and third waves in Dhaka Medical College
Authors:
1. Dr. Reaz Mahmud FCPS, MD, Assistant Professor, Department of Neurology, Dhaka
Medical College. Dhaka, Bangladesh. Phone-+8801912270803. <u>E-mail-</u>
reazdmc22@yahoo.com and rmahmudneuro@dmc.gov.bd. ORCID ID-0000-0002-9427-
1746.
2. Dr. Md. Ashikul Islam, MD, Indoor Medical Officer, National Institute of
neurosciences and Hospital. Dhaka, Bangladesh. phone: 01737104013, mail-
ashikdmc62@gmail.com, ORCID ID -0000-0001-8331-1362
3. Dr. Md. Emdadul Haque, MD, Medical officer, Department of Neurology, Dhaka
Medical College. Dhaka, Bangladesh. phone: 0714560256, <u>mail-</u>
dr.emdadmithu@gmail.com, ORCID ID 0000-0001-6870-6075
4. Dr. Md. Dewan Azmal Hussain, Assistant professor, National Institute of Chest
diseases and Hospital, Phone: +8801819449812, Mail: azmal.dr@gmail.com
5. Dr. Mohammad Rafiqul Islam, Associate professor, Department of Medicine, shaheed
Suhrawardy Medical college. Phone-+8801624413595, Mail: drrafiq73@yahoo.com.
6. Dr. Farhana Binte Monayem, MBBS, Medical officer, Sarkari karmachari Hospital.
Dhaka, Bangladesh. Phone-+8801920155971. Mail-farhanabintemonayem@gmail.com.
ORCID ID-0000-0001-5023-0638.
7. Dr. Mostofa Kamal, MD, Assistant professor, Department of Medicine. Dhaka Medical
College. Phone-+8801711582960, mail- mkamal052@gmail.com

- 8. Dr. Hashmi Sina MRCP, MD, Assistant professor, Department of Neurology, Dhaka 24 Medical College. Dhaka, Bangladesh. Phone-+88017189675269, E-mail: 25 hashmi.sina49@gmail.com 26 9. Dr. Mohammad Fakhrul Islam, MD, Assistant professor, Department of Neurology, 27 College. Dhaka, Bangladesh. Phone-+88001937859810, mail-28 Dhaka Medical 29 fakhrulislam.work@gmail.com. 10. Dr. Ponkaj Kanti Datta, Assistant professor, Department of Medicine, Dhaka Medical 30 Phone College, Bangladesh. 31 Dhaka, number: +8801711069701.Mail-32 ponkajdatta@yahoo.com. ORCID ID: 0000-0002-4508-4549
- 11. Dr. S.K. Jakaria Been Sayeed, MRCP, Indoor Medical Officer, National Institute of
   neurosciences and Hospital. Dhaka, Bangladesh Phone- +8801783335147. Mail skjakaria1@gmail.com. ORCID ID-0000-0003-1173-4248.
- 36 12. Dr. Sabbir Ahmed Dhali, MD, Registrar, Department of Neurology, Dhaka Medical
   37 College. Dhaka, Bangladesh. Phone-+8801720015583. Mail-dr.sabbirdhali@gmail.com.
- 38 13. Dr. Khairul Islam, FCPS. Junior consultant, Department of Medicine, Dhaka Medical
  39 College, Dhaka, Bangladesh. phone-+8801717696207. Mail40 khairul0696207@gmail.com, ORCHID: 00 00000188716270.
- 41 14. Dr. Rifat Hossain Ratul, Medical Officer, COVID-19 post-acute care and follow-up
   42 clinic, Dhaka Medical College. Phone:01631907154, Mail: <u>dr.ratulrifat@gmail.com</u>.
- 43 15. Dr. SK Md. Rubaed Hossain, Research Assistant, Stroke registry, Department of
- 44 Neurology, Dhaka Medical College. Dhaka, Bangladesh, Phone: 01680888637, Mail:
- 45 dr.rubaed94@gmail.com.

It is made available under a CC-BY 4.0 International license .

- 46 16. Habib Naziat Prince, MSC, Research Assistant, North South University, phone:
   47 +8801647237397. Mail- habib.52statru@gmail.com
- 48 17. **Dr. Ahmed Hossain Chowdhury**, MD, Associate Professor, Department of Neurology,
- 49 Dhaka Medical College. Dhaka, Bangladesh. Cell no: +88001712257206. <u>Mail:</u>
  50 ahmedssmc17@yahoo.com.
- 51 18. Dr. Kazi Gias Uddin Ahmed, Associate Professor and Head, Department of Neurology,
   52 Dhaka Medical College. Dhaka, Bangladesh. Phone-01611272277 mail 53 kazi17k43@gmail.com. ORCID ID-0000-0002-0163-8271
- Dr. Md.Titu Miah, Principal and Professor of Medicine, Department of Medicine,
   Dhaka Medical College, Dhaka, Bangladesh. Mobile: +8801711591770. Mail:
   titum21@gmail.com
- Dr. Md. Mujibur Rahman FCPS, MD, FACP Professor, Department of Medicine,
   Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh Phone 01711525406 Mail-mmrahman61@gmail.com. ORCID Identifier: 0000-0002-4381 1511.
- 61 Data availability statement: The data will be within the paper and uploaded as supplementary62 file.
- A funding statement: This research received grant from Director General of Health Services,
  Government of the peoples' republic of Bangladesh.
- 65 **Conflict of interest disclosure:** The authors declare that there is no conflict of interest.
- 66 Ethics approval statement: The Institutional Ethical Committee of Dhaka Medical College

approved the study (ERC-DMC/ECC/2021/55).

3

- **Patient consent statement:** As we mainly reviewed hospital data, there was no scope for written
- 69 consent. We took verbal permission from the patient for post-covid follow-up.
- **Permission to reproduce material from other sources:** Not applicable
- 71 Clinical trial registration: Not applicable

- 74 Corresponding Author:
- 75 Dr. Reaz Mahmud,
- 76 Assistant Professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh.
- 77 Phone-+8801912270803.
- 78 <u>E-mail-reazdmc22@yahoo.com</u>. <u>rmahmudneuro@dmc.gov.bd</u>.
- 79 ORCID ID-0000-0002-9427-1746

91	
92	
93	Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19
94	among first, second, and third waves in Dhaka Medical College
95	Abstract:
96	Background
97	This study aimed to examine the differences in epidemiologic and disease aspects among
98	patients with COVID-19
99	Methods:
100	We reviewed the hospital records between April 2020 and September 2021 and followed up on
101	the patients for post-COVID complications.
102	Findings:
103	Older adult patients were predominantly affected during the first and second waves, followed by
104	middle-aged patients. Men were predominantly admitted, considering the three waves; although
105	more women were admitted in the second wave. Cough was more common in the second and
106	third waves than in the first wave 522 (59.7%). Respiratory distress was the most common in the
107	third wave, 251(67.1%), and least common in the first wave 403 (46.1%). Anosmia was more
108	common in the third wave 116 (31.2%). In the third wave, patients presenting in a critical state
109	23 (6.2%) and severe disease 152 (40.8%) were more common. The hospital admission median
110	(IQR) was longer in the first wave, 12 (8–20), than in other waves. More patients were admitted
111	in the first wave (52%) than in the other waves, and patients received more oxygen in the third
112	wave (75%) than in the other waves. Death occurred more commonly in the first wave (51%)
113	than in the other waves. Patients were investigated more commonly in the first and third waves

It is made available under a CC-BY 4.0 International license .

than in the second wave. The positivity rate was high in the third wave (22.8%) than in other
waves. In the third wave, the positivity rate was higher in women (24.3%) than in men. Postcovid cough increased in the second wave and fatigue was higher in the third wave than in other
waves. Tiredness and memory loss was greater during the second wave than in other waves. **Conclusion:**

This study revealed that the presenting symptoms, outcomes, and epidemiologic trends differedduring the COVID-19 waves.

# 121 Introduction

On December 31 World Health Organization (WHO) formally reported a case of atypical pneumonia in Wuhan City, China [1], which was later named coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. On March 11, 2020, WHO declared the novel coronavirus (COVID-19) outbreak a global pandemic [3].

The WHO classified the phases of the pandemic as phases 1-3 (predominantly animal infection. 126 few human infections), phase 4(sustained human-to-human infection), phases 5 and 6 127 (widespread human infection), post-peak (possibility of recurrent events), and post-pandemic 128 (disease activity at seasonal level) [4]. Most of the worst pandemics lasted for several years [5]. 129 130 After studying the transmission dynamics of SARS-CoV-2, researchers postulated that it would reach long-term circulation within the next five years [6]. Experience in the last 2 years has 131 revealed that resurgence as "waves" is common [4], and the overall pattern of the coronavirus 132 133 pandemic has been a series of increased COVID-19 waves: which gradually declines. Several outbreaks of illnesses have occurred in various parts of the world. Europe entered its third phase 134 in March 2021 [7], and the United States is likely to experience the 4th wave [8]. The reason for 135

It is made available under a CC-BY 4.0 International license .

the seasonal variation in transmission, duration of immunity, degree of cross-immunity between 136 SARS-CoV-2 and other coronaviruses, intensity and timing of control measures [7], and not the 137 least viral mutation can all explain the wave and gradual decline of cases (waves of the disease). 138 [10]. SARS-CoV-2 has mutated at a pace of about 1-2 mutations per month throughout the 139 current global crisis [11]. A variant of SARS-CoV-2 with the D614G mutation emerged in China 140 141 in late January and early February 2020 and immediately became the dominant form of the virus circulating globally [10]. Subsequently, several mutations were recognized as mutations of 142 concern, naming the UK variant known as 501Y. V1, VOC 202012/01, and B.1.1.7, a South 143 144 African variant known as the 501Y. V2, or B.1.351, a Brazilian variant known as 501Y. V3 or P.1 lineage [11, 12, 13], and the Indian variant B.1.617 (double mutant) [14]. The Indian variant 145 gave rise to India's second wave and stressed its health system. In terms of test positivity rates 146 147 (TPRs) and case fatality rates (CFRs), the epidemiologic characteristics seem to differ from those of the first wave [15]. Bangladesh reported the peak of the second wave in late February 2021 148 and the third wave in June 2021 [16]. In the second wave, death rate increased among the young 149 [17]. The African variant was responsible for more than 80% of the second wave, while the delta 150 variant was responsible for 78% of the third wave [17,18]. Preliminary reports of various SARS-151 CoV-2 mutant strains show transmissibility, severity, and case mortality diversity. The initial 152 study about the African variant reported no significant correlation between severe disease and 153 outcomes. However, higher transmissibility is possible. The mutant virus behavior in 154 155 Bangladeshi populations remains largely unknown.

156 Therefore, this study aimed to systematically and scientifically observe the difference in the 157 presentation and outcome of patients with COVID-19 between the first, second, and third waves.

7

It is made available under a CC-BY 4.0 International license .

158 Additionally, we examined the positivity rate, hospital admission rate, and death rate in 159 outpatient department patients.

# **160** Materials and Methods

161 This study aimed to examine differences in the epidemiology of COVID-19 in the first, second,

and third waves. We aimed to find if there were any variations in the symptoms, disease severity,

163 case fatality, length of hospital stay, frequency of patients requiring oxygen therapy, and referrals

to the intensive care unit (ICU). We reviewed the outpatient data for clinic attendance, hospital

admission rate, and death in the outpatient department. We examined the virology laboratory

data to observe differences in the positivity rate, number of tests, and age and sex. We reviewed

167 inpatient hospital data for rates of hospital admission and death. We found differences in

168 complications of COVID-19 in patients followed up for at least 6 months after hospital discharge

169 during the first, second, and third waves of COVID-19.

## 170 Study area and period

The study was conducted at Dhaka Medical College Hospital between January 01, 2021, andJune 20, 2022.

# 173 Study design

We conducted a cross-sectional study and a review of the hospital records. We reviewed the
hospital records of outpatients, inpatients, and virology departments. We examined the patients'
medical. Some patients were followed up for at least 6 months after discharge for post-COVID19 complications. The telephone interviews followed pre-specified telephone interview
guidelines.

8

It is made available under a CC-BY 4.0 International license .

### **Source population**

180 The Dhaka Medical College Hospital inpatient were the source population.

# **181** Study population

182 The study population included inpatients and patients who called back at least 6 months after

183 follow-up.

# 184 Eligibility criteria

- 185 The study included patients' records, containing important demographics such as age, sex, area
- 186 of residence, telephone number, complete treatment sheet, admission and discharge date, and at
- 187 least a brief history. Patients more than 18 years of age, with RT-PCR positive test results
- irrespective of the severity of the disease admitted between April 2020 and September 2022 were
- included in this study for analysis and follow-up.

### 190 Sample size determination

191 The sample size was calculated using the formula below, and the hypothesis was that there was 192 no variation in presentation between the COVID-19 waves in Bangladesh during the pandemic:

193 
$$n = \frac{\left[Z\alpha\sqrt{2p(1-p)} + Z_{\beta}\sqrt{p_1(1-p_1) + p_2(1-p_2)}\right]^2}{(p_1 - p_2)^2}$$

Here,  $Z\alpha=1.96$  Z value of standard normal distribution at 95% confidence interval, P1=prevalence of severe infection in the first wave, P2=Prevalence of severe disease in the second wave, RR=1.5[risk ratio], P2= 0.12; in one study in Bangladesh, the prevalence of severe infection was 11.5% [19], P1=RR×p2=0.18, Zβ=0.84 at 80% power, P= (p1+p2) ÷2=0.15. Thus, the estimated sample size was 240 for each wave.

### **199** Sampling technique and procedure

It is made available under a CC-BY 4.0 International license .

- 200 Cluster sampling methods were used. We compiled a list of all wards where patients with
- 201 COVID-19 had been admitted. We selected one male ward and one female ward. We
- subsequently reviewed all records that met the inclusion and exclusion criteria. We selected post-
- 203 COVID follow-up with non-random sampling methods.

### 204 Study variables

- 205 The variables included in the study were
- 206 **Demographic variable:** Age of the respondents in years and sex
- 207 Presenting features of COVID-19: Fever, cough, respiratory distress, sore throat, nausea,
  208 vomiting, diarrhea, and body ache.
- Investigations in COVID-19 state: Total blood count, CRP, D-dimer, creatinine, and ferritin
  levels.
- 211 COVID-19-severity: COVID-19 positivity, symptoms in case of COVID-19 positivity
- 212 (asymptomatic, mild, moderate, severe, or critical)
- **Duration:** Duration between symptom onset and hospital admission, length of hospital stay.
- 214 **Post-COVID-19 conditions:** Fatigue, cough, respiratory distress, insomnia, etc.
- 215 Outcome-related questions: Discharged and death. Oxygen requirement, ICU referral
- **Functional impact:** We examined functional implications in the post-covid state for at least 6
- 217 months for overall functional status, fatigue score, and depression score.
- 218 **Operational definition:** Confirmed Covid-19, and its different severities were defined according
- to the WHO and National guidelines [19, 20].
- 220 Case fatality rate:

It is made available under a CC-BY 4.0 International license .

221	$CFR = \frac{NUMBER OF TOTAL DEATH SURING THE SAME PERIOD IN THE SAME WARD}{NUMBER OF TOTAL ADMISSION IN THE DEFINED PERIOD IN THE SELECTED WARD}$
222	X100
223	
224	Duration of hospital stay: The total period from the day of admission to the day of discharge.
225	Waves of infection: The first, second, and third waves extend between April 2020 to January
226	2020, February 2021 and May 2021, and June 2021 and September 2021, respectively [21,22].
227	Post-COVID-19 condition: According to the Center for Disease Control, USA [23]
228	Post-COVID conditions include a wide range of new, returning, or ongoing health problems that
229	people experience after contracting the SARS-CoV-2 causing COVID-19.
230	Post-COVID fatigue: The diagnostic criteria for post-COVID-19 fatigue were developed
231	according to the United States Institute of Medicine symptom criteria [24].
232	The Chalder Fatigue Scale [25], the Karnofsky Performance Status Scale [26], and the
233	depression scale were used to assess fatigue severity, overall functional status, and depression
234	[27].
235	Data collection instrument
236	For patients admitted to the hospital, data were collected on a data collection sheet. A telephone
237	directory was used for Post COVID-19 follow-up. We collected data from reports of outpatient,
238	inpatient, and virology departments.

# 239 Data Collection procedure

We collected all patients' files from the hospital record unit in the selected ward. Each file wasevaluated by one data collector and researcher. The completed data collecting sheet contains a

- 242 list of all available information. We obtained no specific procedure for missing data and
- excluded files that did not contain essential information, such as patient demographics,

It is made available under a CC-BY 4.0 International license .

admission date, and discharge date. We collected the phone number from the hospital records

and interviewed the patients for post-covid -19 complications at least 6 months after recovery.

246 We collected data from the outpatient, inpatient, and virology departments using the Excel

247 datasheet, which contains the patient's name, age, sex, date of attendance, outcome, admission,

248 death, discharge, positive or negative status, etc.

## 249 **Data Quality Control**

Each data sheet was reviewed by two researchers; disagreements were resolved through

discussion. We removed responses where respondents provided contradictory answers. Because

each patient was coded and had a specified hospital record number, there was no scope for

253 double responses.

## **Data Processing and Analysis**

255 R (v4.1.1) was used to process data. We performed a network analysis with a tidy verse and q graph. Qualitative data with normal distribution were expressed as means (SD), while non-256 normal data were expressed as medians (IQR). We divided the respondents into groups of first, 257 258 second, and third waves. We used the chi-square test to calculate quantitative data and one-way ANOVA to calculate quantitative data. A needed we used a post hoc analysis with Bonferroni 259 260 adjustment, Dunn test, and Tukey's test. We determined epidemiological trends in the EXECL 261 sheet. The p-value for statistical significance was set at <0.05. We did not impute any missing 262 values, and they were included in the analysis.

# 263 Ethical consideration

It is made available under a CC-BY 4.0 International license .

- 264 The Institutional Ethical Committee of Dhaka Medical College approved this study (ERC-
- 265 DMC/ECC/2021/55). As we mainly reviewed the hospital data, there was no need for written
- consent. The patients provided verbal consent for post-covid follow-up.

# 267 **Results**

We reviewed 1766 patient records and included 1597 patients' data for analysis in this mixed study of retrospective hospital review of hospital data and cross-sectional follow-up of patients admitted for post-COVID-19 complications. From these patients we followed 600 patients over the telephone for post-COVID-19 complications. Between April 2020 and September 2021, and 38578 patients visited the outpatient department, 24501 patients were admitted, 57857 were tested for treatment at the virology department (Suppliment1).

Table 1: Demographic characteristics and co-morbidity of the admitted patients in the three waves

Variable	Categories	Total patient	First wave <sup>a</sup>	Second	Third wave <sup>c</sup>	Р
		(n=1595)	(n=874)	wave <sup>b</sup>	(n=372)	value
		(N)	(N) %	(n=349)	(N) %	
				(N) %		
Age		47.91(15.67)	43.82(14.31)	50.79(15.95)	54.62(15.61)	< 0.001
(n=1597),						
mean (SD)						
	<40 years	512	364	84	64	
		32.1%	41.6%	24.1%	17.2%	

Age						< 0.001
(n=1595)	40-60	652	366	139	147	_
	years	40.8%	41.9%	39.8%	39.5%	
	60+ years	431	144	126	161	_
		27.02%	54.8%	36.1%	43.3%	
	<b>F</b> 1	(27	202	101	152	
	Female	627	283	191	155	
sex		39.31%	32.4%	54.7%	41.0%	< 0.001
(n=1595)	Male	968	590	158	220	
		60.68%	67.6%	45.3%	59.0%	
Fever	Present	1366	738	296	332	
(n=1595)		85.6%	84.4%	85.1%	89.0%	0.1
Cough	Present	1040	522	228	290	
(n=1595)		65.2%	59.7%	65.5%	78.0%	< 0.001
Running	Present	206	143	16	47	
nose		12.9%	16.4%	4.6%	12.6%	< 0.001
(n=1595)						
Respiratory	Present	848	403	194	251	
distress		(53.1)	46.1%	55.7%	67.1%	< 0.001
(n= 1595)						
Sore throat	Present	278	198	33	47	
(n=1595)		17.4%	22.7%	9.5%	12.6%	< 0.001

Hoarseness	Present	24	11	5	8	
of voice		1.5%	1.3%	1.4%	2.1%	0.50
(n=1595)						
Chest pain	Present	107	52	19	36	
(n=1595)		6.7%	6.0%	5.4%	9.6%	0.03
Diarrhea	Present	152	74	18	60	
(n= 1595)		9.5%	8.5%	5.2%	16.1%	< 0.001
Vomiting	Present	96	29	8	59	
(n= 1595)		6.1%	3.3%	2.3%	15.9%	< 0.001
Anorexia	Present	274	123	38	113	
(n=1594)		17.1%	14.1%	11.0%	30.2%	< 0.001
Anosmia	Present	301	158	27	116	
(n=1593)		18.8%	18.1%	7.8%	31.2%	< 0.001
Headache	Present	252	145	25	82	
(n=1583)		15.7%	16.6%	7.2%	22.5%	< 0.001
Lethargy	Present	436	231	106	99	
(n=1597)			26.4%	30.4%	26.5%	0.35
Body ache	Present	286	107	87	92	
(n=1596)			12.2%	25.0%	24.6%	< 0.001
	Critical <sup>f</sup>	25	0	2	23	
		1.5%	0.0%	0.6%	6.2%	
	Mild <sup>g</sup>	747	422	216	109	-
Presenting		29.7%	48.3%	61.9%	29.2%	< 0.001

severity <sup>d</sup>						
(n=1595)	Moderate <sup>h</sup>	648	443	116	89	-
		40.6%	50.7%	33.2%	23.9%	
	Severei	175	8	15	152	-
		10.9%	0.9%	4.3%	40.8%	
	Critical <sup>f</sup>	107	32	3	72	
			3.7%	0.9%	19.3%	
Ultimate	Mild <sup>g</sup>	627	365	183	79	-
severity <sup>e</sup>			41.8%	52.9%	21.1%	< 0.001
(n=1595)	Moderateh	589	383	128	78	-
			43.8%	37.0%	20.9%	
	Severe <sup>i</sup>	271	94	32	145	-
			10.8%	9.2%	38.8%	
Diabetes	Present	531	216	136	179	
(n=1151)		33.2%	28.4%	38.8%	48.1%	< 0.001
Hypertension	Present	532	182	142	208	
(n=1154)		33.3	24.5%	40.6%	55.9%	< 0.001
Asthma	Present	114	57	30	27	
(n=931)		7.1%	8.0%	8.5%	16.0%	< 0.001
IHD	Present	123	29	31	63	
(n=930)		7.7	4.1%	8.8%	16.9%	< 0.001
Renal	Present	103	24	32	47	
disease		6.4%	3.4%	9.1%	12.6%	< 0.001

It is made available under a CC-BY 4.0 International license .

	(n=926)							
	<ul> <li>a- From April 2020 to January 2020,</li> <li>b- From February 2021 to May 2021</li> <li>c- From June 2021 to September 2021</li> <li>d- The severity of the patient at the time of hospital admission</li> <li>e- The severity of the patient in the course of the hospital stays</li> <li>f- Critical: Patient requiring high flow oxygen or mechanical ventilation</li> <li>g- Mild: Patients having mild symptoms of upper respiratory tract viral infection, including mild fever, cough (dry), sore throat, nasal congestion, malaise, headache, muscle pain, anosmia, or malaise;</li> <li>h- Moderate: the patient has respiratory symptoms such as cough and shortness of breath are present without signs of severe pneumonia (tachypnea &gt;30 breaths/min and hypoxia: oxygen saturation &lt;90% on room air).</li> <li>i- Severe: Patients with severe pneumonia require supplemental oxygen through nasal canal, facemask, or face mask with reservoir.</li> </ul>							
276								
277								
278	The mean ag	ge (SD) of the h	ospital-admitte	d patients was 4	7.91(15.67) ye	ars, with patien	ts in the	
279	and third wa	ves being highe	er than those in	the first wave (	p <0.001). Patie	ents above 60 y	ears	
280	were mainly	involved in the	e first wave 144	(54.8%), the 40	)–60 age group	was primarily	involved	
281	in the second	1 wave 139 (39	.8%), and those	above 60 years	were more like	ely to be infecte	ed in the	
282	third wave 1	61 (43.3%).						
283 284	Men were predominantly admitted 968 (60.68%). However, in the second wave, the number of women, 191 (54.7%), was higher.							
285	Fever was pr	resent in 1366 (	(85.6%) patients	s and did not dif	fer among the t	hree waves (p	= 0.1).	
286	Cough was r	nore prevalent	in the second 2	88 (65.5%) and	third waves 29	0 (78%) than in	the first	
287	wave 522 (5	9.7%). Runninş	g nose was mos	t prevalent in th	e first wave, 14	3 (16.4%), and	least	
288	prevalent in	the second wav	ve, 16 (4.6%). R	Respiratory distr	ess was the mos	st prevalent in t	he third	
289	wave, 251 (6	57.1%), and the	least prevalent	in the first wav	e, 403 (46.1%).	Sore throat oc	curred	

more prevalent in the first wave 198 (22.7%) than in the other waves. Diarrhea 60 (16.1) and

It is made available under a CC-BY 4.0 International license .

vomiting 59 (15.9%) were the most prevalent in the third wave. Anosmia was more prevalent in

- the third wave 116 (31.2%) than in other waves and less frequently in the second wave 27 (7.8%)
- than in other waves. However, headache was more prevalent in the third 82 (22.5%) and first
- wave 145 (16.6%) than in the second wave. Body aches occurred more commonly in the second
- 87 (25%) and third 92 (24.6%) waves than in the first wave. (Table 1)
- Patients that presented in a critical condition 23 (6.2%) and severe disease 152 (40.8%) were
- 297 more prevalent in the third wave than in other waves. In the second wave, most cases were mild
- 298 216 (61.9%). During the hospital stay, the severity of the patient's severity changed, and in the
- third wave, 72 (19.3%) critical and 145 (38.8%) severe diseases emerged. Mild-to-moderate
- 300 illness was more common in the first and second waves than in the third wave.
- 301 Diabetes was more common among admitted patients in the second 136 (38.8%) and third waves
- 179 (48.1%) than in the first wave. Hypertension was prevalent in the second 142 (40.6%) and
- third wave 208 (55.9%). Asthma 27 (16%), ischemic heart disease 63 (16.9%), and renal disease
- 47 (12.6%) were the most prevalent in the third wave (Table 1).

# 305 Symptoms Cluster in COVID-19

We found three clusters of symptoms among the admitted COVID patients: 1. Fever, cough, and

respiratory distress. 2. Anosmia, headache, and anorexia 3. Sore throat and running nose. The

- 308 symptom clusters differed for the three waves. In the first wave, we found three clusters; 1.
- Respiratory distress and cough. 2. Anosmia and anorexia. 3. Running nose and sore throat. In the
- second wave, we found a cluster of headaches, running nose, sore throat, and hoarseness of
- voice. In the third wave, we found three clusters: 1. anorexia and anosmia, 2. fever and cough,
- and 3. headache, diarrhea, and vomiting. (Figure 1)

It is made available under a CC-BY 4.0 International license .

#### 313 Figure 1: Symptoms clusters in COVID-19.

#### **Table 2: Investigation profile of the admitted patients in the three waves**

315

Variable	Total	First wave	Second wave	Third wave	P value
	patient	Median (IQR)	Median (IQR)	Median (IQR)	
	(N)				
WBC	607	8.50	18.65	5.95	< 0.001
		(6.2-11.72)	(14.55-24.00)	(1.28-10.23)	
Neutrophil	595	71.70	83.00	78.00	< 0.001
(%)		(60.92-83.00)	(79.0-87.0)	(68.0-86.0)	
Lymphocyte	595	21.75	12.00	18.00	< 0.001
(%)		(12.88-30.68)	(10.70-16.0)	(10.0-27.0)	
Platelet count	575	247.00	126.00	135.00	< 0.001
		(189.5-324.0)	(29.9-276.00)	(31.00-250.00)	
CRP	438	12.00	18.00	39.00	< 0.001
		(6.0-34.77)	(8.68-68.50)	(13.0-85.0)	
creatinine	547	0.96	1.180	1.14	< 0.001
		(0.80-1.12)	(0.95-6.62)	(0.90-1.40)	
D-dimer	458	0.47	1.52	0.79	< 0.001
		(0.27-1.05)	(0.62-3.56)	(0.40-1.80)	
Ferritin	369	297.00	1468.00	441.00	0.002
		(122.0-642.0)	(973.5-2050.0)	(235.5-1000.0)	

It is made available under a CC-BY 4.0 International license .

Serum	191	-	138.00	135.00	0.121
sodium			(135.0-140.8)	(132.0-138.0)	

316

The white blood cell count was high in the second wave, 18.65(14.5–24), and low in the third wave. The platelet count was low in the third wave 78 (68–86). CRP was much higher in the third wave 39 (13–85) and D-dimer 1.52 (0.63–3.56), and ferritin was high in the second wave 1468 (973–2050). (Table 2)

#### 321 Table 3: Outcome of the admitted patient in three waves

322

Variable	Categories	Total	First	Second	Third wave	Р
		patient	wave (N)	wave (N)	(N)	value
		(N)	%	%	%	
	Critical	107	32	3	72	
			29.9%	2.8%	67.3%	
Ultimate	Mild	627	365	183	79	
severity			58.2%	29.2%	12.6%	< 0.001
	Moderate	589	383	128	78	
			65.0%	21.7%	13.2%	
	Severe	271	94	32	145	
			34.7%	11.8%	53.5%	
Duration of			13.0	12.0	7.0	
hospital stay			(8.0-	(8.0-12.0)	(4.0-11.0)	<0.001

It is made available under a CC-BY 4.0 International license .

		20.0)			
Interval		5.0	5.0	5.0	< 0.001
symptom		(4.0-6.0)	(5.0-6.0)	(4.0-6.0)	
onset and					
admission					

323

- 324 The patient developed a more severe disease in the third wave, and the duration of hospital stay
- was longer in the first wave 12 (8–20). (Table 3)

326

#### 327 Table 4: Trend of outpatient, inpatient and virology department consultation in three

328 waves

Trait	Total	First wave	Second wave	Third wave	P value
		Outpatient de	epartment		
	l		1		
Total Attended	38578	19890 (51.6)	7347 (19.0)	11341 (29.4)	
Positive	5584	3134 (15.7%)	896 (12.1%)	1554	< 0.001
				(13.7%)	
Admitted	25721	13650	5419 (73.7%)	6652	< 0.001
		(68.6%)		(58.6%)	
Death	329	127 (0.6%)	105 (1.4%)	97 (0.8%)	
Admission rate	81.3	80.6	84.4	80.1	
(%)					
Gender					

Male					
Total Attended	22595	12274 (54.3)	4341 (19.2)	5980 (26.5)	
Positive	3201	1895 (15.4%)	518 (11.9%)	788 (13.1%)	< 0.001
Admitted	15133	8541 (69.5%)	3218 (74.1%)	3374	<0.001
				(56.4%)	
Death	208	86 (0.7%)	64 (1.4%)	58 (0.9)	
Admission rate	81.6	81.2	84.7	80.0	
(%)					
Female					
Total Attended	15981	7614 (47.6)	3006 (18.8)	5361 (33.5)	
Positive	2383	1239 (16.2%)	378 (12.5%)	766 (14.2)	<0.001
Admitted	10586	5107 (67%)	2201 (73.2%)	3278	<0.001
				(61.1%)	
Death	121	41 (0.5%)	41 (1.3%)	39 (0.6%)	
Admission rate	80.9	80.0	84.0	80.3	
(%)					
Age group					
<40 years					
Total Attended	14264	7297 (51.2)	2354 (16.5)	4613 (32.3)	
Positive	1623	1021 (13.9)	221 (9.3)	381 (8.2)	<0.001
Admitted	6266	3547 (48.6)	1162 (49.3)	1557 (33.7)	<0.001
Death	49	20 (0.2)	13 (0.5)	16 (0.3)	
Admission rate	79.0	77.3	83.2	79.7	

(%)					
40-60 years					
Total Attended	12759	6920 (54.2)	2457 (19.3)	3382 (26.5)	
Positive	2097	1177 (17)	356 (14.4)	564 (16.6)	<0.001
Admitted	9314	5099 (73.6)	1948 (79.2)	2267 (67)	< 0.001
Death	121	42 (0.6)	45 (1.8)	34 (1)	
Admission rate	80.8	80.7	82.9	79.1	
(%)					
60+ years					
Total Attended	11490	5645 (49.1)	2516 (21.9)	3329 (29.0)	
Positive	1852	929 (16.4)	316 (12.5)	607 (18.2)	< 0.001
Admitted	10101	4979 (88.2)	2300 (91.4)	2822 (84.7)	< 0.001
Death	153	64 (1.1)	47 (1.8)	42 (1.2)	
Admission rate	83.4	83.4	86.4	81.3	
(%)					
		Inpatient cor	isultation		
Trait	Total	First wave	Second wave	Third wave	P value
		N (%)	N (%)	N (%)	
Total	24501	12797 (52.2)	5317 (21.7)	6387 (26.1)	0.0004
admission					
Oxygen	14198	6865 (48.4)	3332 (23.4)	4001 (28.2)	<0.0001
support					
Percentage of		61.8%	69.43%	75.29%	<0.0001

the patient									
getting oxygen									
ICU admission	4030	3442 (26.8%)	588 (11%)		<0.0001				
Death	5057	2584 (20%)	1019 (19%)	1454	<0.0001				
				(22.7%)					
	Virology department								
Trait	Total	First wave	Second wave	Third wave	P value				
		N (%)	N (%)	N (%)					
Total									
population									
Total test	57857	26708 (46.1)	13214 (22.8)	17935 (31.0)					
Positive	12870	5962 (46.3)	2814 (21.9)	4094 (31.8)	<0.001				
Positivity rate	22.2%	22.3	21.3	22.8					
(%)									
Gender									
Male									
Total test	32517	15146 (46.6)	7591 (23.3)	9780 (30.1)					
Positive	7082	3416 (48.2)	1553 (21.9)	2113 (29.8)	<0.001				
Positivity rate	21.8	22.6	20.5	21.6					
(%)									
Female									
Total test	25312	11542 (45.6)	5619 (22.2)	8151 (32.2)					
Positive	5782	2542 (44.0)	1260 (21.8)	1980 (34.2)	< 0.001				

It is made available under a CC-BY 4.0 International license .

Positivity rate	22.8	22.0	22.4	24.3	
(%)					
Age group					
inge group					
<40					
Total test	27055	13408 (49.6)	5291 (19.6)	8356 (30.9)	
Positive	5555	2721 (49.0)	1063 (19.1)	1771 (31.9)	<0.001
Positivity rate	20.5	20.3	20.1	21.2	
(%)					
40-60					
Total test	13033	6215 (47.7)	2570 (19.7)	4248 (32.6)	
Positive	3148	1538 (48.9)	582 (18.5)	1028 (32.7)	< 0.001
Positivity rate	24.2	24.7	22.6	24.2	
(%)					
>60					
Total test	8210	3477 (42.4)	1678 (20.4)	3055 (37.2)	
Positive	2114	911 (43.1)	369 (17.5)	834 (39.5)	< 0.001
Positivity rate	25.7	26.2	22.0	27.3	
(%)					

329

Confirmed COVID-19 cases were higher (15.7%) in the second wave than in the other waves, the admission rate 73.7%, and the death rate 1.4% were higher in the second wave than in other waves. The proportion of confirmed COVID-19 cases was higher among women in all waves. In the third wave, the admission rate among women 61.1% was higher than among men. The

number of positive cases was higher in those below 40 years in the first wave 13.9% and above 334 60 years in the third wave 18.2%. The admission rate of patients below 40 years was lower in the 335 third wave 33.7%. In the second wave, the admission rate among the 40–60-year age group 79%336 and above 60 years age group 91.4% was higher than in other waves. In the second wave, the 337 death rate was higher among men 1.4% and women, 1.3% In the second wave, the death rate was 338 339 high in the 40–60-year age group and above 60-year age group. The admission rate was higher in patients aged above 60 years in all three waves. 340 52% of patient were admitted in the first wave and 75% received more oxygen in the third wave. 341 342 Death was more common 51% in the first wave. The patient was tested more frequently in the first and third waves than in the second wave. The 343 positivity was high in the third wave 22.8%. In the third wave, the positivity rate was high among 344 women 24.3%. The incidence rate of patients above 60 years was high in the first and third 345 waves 27.3%. (Table 4) 346 The daily COVID-19 infection rate was higher in the third wave and the duration of the second 347 wave was short. The first wave lasted longer than the other wave, with an elevated and gradual 348 infection rate decline. 349 The rate of testing was equal for all three waves. The positivity rate was higher during the third 350 than in the first and second waves (Figure 2, Supplement 2). 351

352

# Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in three waves

#### **Table 5: post COVID -19 complications of the three waves**

Trait	Total patient	First wave	Second wave	Third wave	P value

	600	200	200	200	
Age, Mean	45.2(15.8)	45.5(16.3)	43.6(14.3)	46.5(16.5)	0.19
(SD)					
Sex, Male n	337(56.2)	123(61.5)	97(48.5)	117(58.5)	0.08
(%)					
Post COVID-1	9 conditions				
Number of post	t-covid condition	IS			0.24
None	40(6.7)	17(8.5)	12(6)	11(5.5)	
Single	93(15.5)	38(19)	30(15.1)	25(12.5)	
Multiple	466(77.7)	145(72.5)	157(78.9)	164(82)	
Symptoms		1	1		I
Feverish	16(2.7)	6(3)	4(2)	6(3)	0.7
feeling					
Fatigue	421(70.2)	126(63)	144(72)	151(75.5)	0.03
Cough	127(21.2)	35(17.6)	58(29)	34(17)	0.004
Respiratory	40(6.7)	14(7)	15(7.5)	11(5.5)	0.7
distress					
Hoarseness of	16(2.7)	9(4.5)	2(1)	5(2.5)	0.09
voice					
Chest pain	142(23.7)	44(22.1)	40(20.1)	58(29)	0.09
Anorexia	135(22.5)	40(20)	39(19.5)	56(28)	0.07
Anosmia	16(2.7)	7(3.5)	4(2)	5(2.5)	0.6
Headache	146(24.3)	46(23)	49(24.5)	51(25.5)	0.08

It is made available under a CC-BY 4.0 International license .

Memory	152(25.4)	46(23)	64(32)	42(21.1)	0.03
disturbance					
Insomnia	73(12.2)	20(10)	29(14.5)	24(11)	0.38
Hypersomnia	4(0.7)	2(1)	2(1)		0.36
Sleep pattern	6(1)	2(1)	2(1)	2(1)	<0.99
alteration					
Arthralgia	69(11.5)	25(12.6)	28(14)	16(8)	0.15
Confusion	29(4.8)	5(2.5)	12(6)	12(6)	0.18
New onset	15(2.5)	2(1)	7(3.5)	6(3)	0.23
hypertension					
New onset	23(3.8)	8(4)	10(5)	5(2.5)	0.42
Diabetes					
Fatigue score,	4.7(2.9)	3.1(2.9)	4.2(3.3)	3.9(3.1)	0.001
mean (SD)					
Functional	90.3(7.4)	90.9(7.7)	90(7.6)	90(6.9)	0.35
status, mean					
(SD)					
Depression	143(25.2)	58(40.6)	49(34.3)	36(25.2)	0.03

356

The percentage of patients that developed post-COVID complications was equal in all three waves. However, patients in the second wave developed more post-covid cough and memory disturbance depression, and patients in the third wave developed more fatigue than those in other waves. However, patients in the second wave had increased fatigue scores. The functional status

It is made available under a CC-BY 4.0 International license .

- 361 of the patients was similar in the three waves. We found five symptom clusters. However, they
- did not differ among the three waves (Figure 3).

#### **363** Figure 3: Symptom cluster in post COVID-state

- 364
- 365

# 366 **Discussion**

This study compared the first, second, and third COVID-19 waves in terms of presentation, 367 outcomes, and hospital epidemiological trends. The first wave lasted longer, and however, the 368 second wave lasted for a short period. We found age and sex differences in the admission rates in 369 the three waves. Cough, runny nose, respiratory distress, diarrhea, vomiting, and anosmia were 370 the most common symptom in the three waves. The symptom cluster differed among the three 371 waves. Disease severity, duration of hospital stay, and severity markers differed. We found 372 373 disparities in the frequencies of the positivity test and death rates. The three waves had similar Post COVID complications. 374

This study was conducted at the tertiary center of Dhaka. The treatment facility differs from center to center and region to region; therefore, we cannot generalize the findings across the nation and globally.

During replication, a mutation in the genetic code of SARS-CoV-2 leads to the development of a new variant. The behaviors of variants, such as virulence and transmissibility, differ [28]. WHO named the variant to be monitored with the Greek alphabet and named from alpha to zeta [29]. In Bangladesh, until September 2021, alpha, beta, and delta variants were dominant at different times creating, three waves of COVID-19: the first wave was caused by alpha, the second wave

It is made available under a CC-BY 4.0 International license .

was caused by beta, and the third wave caused by delta variants [18]. Epidemiological and
disease characteristics differ in various studies [16,30,31].

In Bangladesh, the first wave lasted approximately 8 months, the second wave approximately 2 months, and the third wave approximately 3 months. This was due to the variations' transmissibility; delta was 63–167% more transmissible than alpha [32]. Therefore, the most susceptible people became infected faster, replacing existing variants. Delta and beta variants spread quickly in Bangladesh, and delta quickly became the dominant variant. Omicron was 2.8 times more transmissible than Delta, thus replacing Delta in a short period [33].

391 In this study, we found a variation in the demographic patterns across the three variants.

Young people were more affected in the initial wave, as evidenced by the high number of 392 positive cases in the virology laboratory among the young. However, the elderly had a higher 393 positivity rate. The proportion of older adult patients in the hospitalized patients was higher in 394 the first and third waves than in the second wave. The admission rate among the attended 395 patients in the outpatient department was higher in the second wave than in the first and third 396 waves. Because of their increased mobility the younger age group became infected in large 397 numbers. Immune senescence and various comorbidities could explain the older adults' 398 399 admission. The viral receptors ACE2 and CD26 are more expressed in senescent cells, which explains why older adults are more susceptible to infection [35]. The virus affinity for the 400 401 receptor varies among the variants. This explains the age group variations among variants [36].

402

The overall number of admitted men was higher than women. However, the number of women
admitted was higher in the second wave. Admission and death rates were higher among men.
However, women had a higher positivity rate than men, especially in the second and third

30

It is made available under a CC-BY 4.0 International license .

406 waves. Men had higher rate of incidence of COVID-19 due to the altered immunologic response, associated comorbidity, hormonal differences, and smoking habits [35]. angiotensin-converting 407 enzyme (ACE) receptor expression is higher in women because its genetic loci are on the X 408 chromosome [37]. The TMPRSS2 gene is located on chromosome 21q22.3[38]. Some variants 409 have a higher affinity for TMPRSS than for ACE II. This might explain the gender differences in 410 411 the expression of the various COVID-19 variants. Again, increased testosterone levels may increase the probability of microthrombi formation [39], which is the underlying 412 pathophysiology of severe COVID-19. 413

The duration of Hospital admission was longer in the first wave, which was most likely due to the severity of the disease at the time of discharge. In the first wave, most patients were admitted because of isolation, and their release was determined by the time of PCR negativity. ICU admission was higher in the first wave due fear an unnecessary patient transfer to the ICU. The death rate was higher in the third wave than in other waves.

The different affinities of the viruses can explain the heterogeneous presentation and clustering of various variants to the receptor. The virus's ability to escape immunity [40] can explain the mutant strain's varied presentation and severity.

The three waves had slightly different post-COVID-19 complications. Further studies on itspathogenesis and immunological response are needed.

Because this was a single-center study, genotyping was either not performed or was impractical
for all patients. This was a retrograde study and a review of the documents. Therefore, missing
information was likely.

# 427 **Conclusion**

428	This study revealed that during the COVID-19 waves, the presenting features, outcomes, and
429	epidemiologic trends were different.

#### 430 **Recommendation**

- 431 In each of the three waves, COVID-19 occurred differently. A mutant strain of the SARS-CoV-2
- 432 was most likely the cause of these differences. Therefore, we recommend the following.
- 4331. There should be genetic surveillance for the identification of the specific variant434 of interest.
- 435436436436436
- 437 3. There should be diversity in each wave's strategy for disease control planning,438 treatment, and hospital management.

# 439 Acknowledgments

We are grateful to Dhaka Medical College Hospital authority for giving us permission to accessthe hospital records; without their help it will be impossible to conduct this study.

442

# 443 **References:**

World Health Organization. GCM teleconference – Note for the Records. 10 January
 2020. Subject: Pneumonia in Wuhan, China. Available from: https: // www. who. int/
 blueprint / 10-01-2020-nfr-gcm.pdf?ua=.

- 447 2. World Health Organization. Novel coronavirus (2019-nCoV). Situation Report 1. 21
- 448 January 2020. Available from: <u>https://www.who.int/docs/default-source /</u>coronaviruse
- 449 /situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10 4.
- 450 3. WHO Director-General's opening remarks at the media briefing on COVID-19 11
- 451 March 2020, available from:<u>https://www.who.int/dg/speeches/detail/who-director-</u>
- 452 general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
- 453 4. <u>https://www.worldometers.info/coronavirus/</u>, Accessed 25 November 2021.
- 454 5. <u>https://www.who.int/influenza/resources/documents/pandemic\_phase\_descriptions\_and\_</u>
- 455 <u>actions.pdf</u>. Accessed 25 November 2021.
- 456 6. <u>https://www.history.com/news/pandemics-end-plague-cholera-black-death-smallpox.</u>
- 457 Accessed 25 November 2021
- 458 7. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the
- 459 transmission dynamics of SARS-CoV-2 through the postpandemic period.
- 460 *Science* 22 May 2020:Vol. 368, Issue 6493, pp. 860-868. DOI: 10.1126/science.abb5793
- 461 8. <u>https://www.theguardian.com/world/2021/mar/22/lockdowns-return-extended-third-</u>
- 462 <u>wave-covid-europe.</u> Accessed 25 November 2021.
- 463 9. <u>https://time.com/5951490/covid-fourth-wave/</u> Accessed 25 November 2021.
- 464 10. <u>https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/.</u> Accessed 25
  465 November 2021.
- 466 11. <u>https://www.nature.com/articles/d41586-020-02544-6</u>. Accessed 25 November 2021.
- 467 12. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/. Accessed 25
  468 November 2021.

- 469 13. European Centre for Disease Prevention and Control 20 Dec 2020 Threat Assessment
- 470 Brief. Accessed 25 November 2021.
- 471 14. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-
- 472 <u>emerging-variants.html</u>. Accessed 19 November 2021.
- 473 15. https://www.who.int/docs/default-source/coronaviruse/situation
- 474 reports/20210427\_weekly\_epi\_update\_37.pdf?sfvrsn=a1ab459c\_5&download=true.
- 475 Accessed 19 November 2021.
- 476 16. Ranjan, R., Sharma, A., Verma, M.K., 2021. Characterization of the Second Wave of
- 477 COVID-19 in India. medRxiv 2021.04.17.21255665. doi: 10.1101/2021.04.17.21255665
- 478 17. <u>https://www.tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/covid-deaths-drop-</u>
- 479 <u>41-lowest-39-days-242425</u>. Accessed 19 November 2021.
- 480 18. <u>https://www.icddrb.org/news-and-events/icddrb-in-the-news.</u> Accessed 19 November
  481 2021.
- 482 19. WHO guidance on management of severe acute respiratory infection (SARI) when
- 483 COVID19 is suspected. Accessed November 1, 2020. //www.who.int/publications-
- 484 detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-
- 485 coronavirus-(ncov)-infection-is-suspected.
- 486 20. National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID-19).
- 487 27 May, 2020. Accessed November 1, 2020.https://dghs.gov.bd/images/docs/Guideline/
  488 COVID. Guideline. pdf.
- 21. Bari R and Sultana F (2021) Second Wave of COVID-19 in Bangladesh: An Integrated
  and Coordinated Set of Actions Is Crucial to Tackle Current Upsurge of Cases and
  Deaths. Front. Public Health 9:699918. doi: 10.3389/fpubh.2021.699918

- 22. Devnath P, Hossain MJ, Emran TB, Mitra S. Massive third wave of COVID-19 outbreak
  in Bangladesh: a co-epidemic of dengue might worsen the situation. Future Virol. 2022
  Jan:10.2217/fvl-2021-0182. doi: 10.2217/fvl-2021-0182. Epub 2022 Mar 8. PMID:
  35284001; PMCID: PMC8906578.
- 496 23. Post-COVID conditions. Centers for disease control and prevention, USA. Accessed 19
   497 July 2021. From <u>https://www.cdc.gov/coronavirus/2019-ncov/long-term-</u>
   498 effects/index.html
- 24. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue
  Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond
  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness.
  Washington (DC): National Academies Press (US); 2015 Feb 10. Available from:
  https://www.ncbi.nlm.nih.gov/books/NBK274235/ DOI: 10.17226/19012.
- 504 25. <u>Chalder, T.</u>; Berelowitz, G.; Pawlikowska, T.; Watts, L.; <u>Wessely, S.</u>; Wright, D.;
- 505 Wallace, E. P. (1993). <u>"Development of a fatigue scale"</u>. Journal
   506 of Psychosomatic Research. 37 (2): 147–153. ISSN 0022-3999. PMID 8463991
- 507 26. Karnofsky D, Burchenal J, The clinical evaluation of chemotherapeutic agents in cancer.
  508 In: MacLeod C, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia
  509 University Press; 1949:191–205.
- 510
- 511 27. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: validity of a brief
  512 depression severity measure. *Journal of general internal medicine*, *16*(9), 606–613.
  513 https://doi.org/10.1046/j.1525-1497.2001.016009606.x

- 514 28. Islam S, Islam T, Islam MR. New Coronavirus Variants are Creating More Challenges to
- 515 Global Healthcare System: A Brief Report on the Current Knowledge. Clin Pathol. 2022
- 516 Feb 3;15:2632010X221075584. doi: 10.1177/2632010X221075584. PMID: 35141522;
- 517 PMCID: PMC8819824.
- 518 29. <u>https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications</u>. Accessed on
- 519 01.11.21
- 520 30. S. Iftimie, A. F. López-Azcona, I. Vallverdú et al., "First and second waves of
- 521 coronavirus disease-19: a comparative study in hospitalized patients in Reus,
- 522 Spain," *PLoS One*, vol. 16, no. 3, Article ID e0248029, 2021.
- 31. Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasivaj B, Kuratong S,
  Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic:
  Retrospective Descriptive Study in Thailand. Adv Prev Med. 2021 Oct 8; 2021:5807056.
  doi: 10.1155/2021/5807056. PMID: 34659835; PMCID: PMC8519693.
- 32. Earnest, R, Uddin, R, Matluk, N, et al. Comparative transmissibility of SARS-CoV-2
  variants Delta and Alpha in New England, USA. Cell Rep
  Med. 2022;3(4):100583. https://doi.org/10.1016/j.xcrm.2022.100583
- 530 33. De La Cruz-Hernández, S., & Álvarez-Contreras, A. (2022). Omicron Variant in Mexico:
- The Fourth COVID-19 Wave. *Disaster Medicine and Public Health Preparedness*, 1-2.
  doi:10.1017/dmp.2022.160
- 533 34. Monod M, Blenkinsop A, Xi X, Hebert D, Bershan S, Tietze S, Baguelin M, Bradley VC,
- 534 Chen Y, Coupland H, Filippi S, Ish-Horowicz J, McManus M, Mellan T, Gandy A,
- 535 Hutchinson M, Unwin HJT, van Elsland SL, Vollmer MAC, Weber S, Zhu H, Bezancon
- 536 A, Ferguson NM, Mishra S, Flaxman S, Bhatt S, Ratmann O; Imperial College COVID-

- 19 Response Team. Age groups that sustain resurging COVID-19 epidemics in the
  United States. Science. 2021 Mar 26;371(6536):eabe8372. doi: 10.1126/science.
  abe8372. Epub 2021 Feb 2. PMID: 33531384; PMCID: PMC8101272.
- 540 35. Al-Bari MAA, Hossain S, Zahan MK. Exploration of sex-specific and age-dependent
- 541 COVID-19 fatality rate in Bangladesh population. World J Radiol. 2021 Jan 28;13(1):1-
- 542 18. doi: 10.4329/wjr. v13.i1.1. PMID: 33574990; PMCID: PMC7852349.
- 36. Han Y, Wang Z, Wei Z, Schapiro I, Li J. Binding affinity and mechanisms of SARS-543 Biotechnol 2021; 544 CoV-2 variants. Comput Struct J. 19:4184-4191. doi: 545 10.1016/j.csbj.2021.07.026. Epub 2021 Jul 26. PMID: 34336146; PMCID: PMC8312055. 546
- 547 37. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and
  548 sex-specific effects in infectious disease susceptibility. Hum Genomics. 2019; 13:2.
- 38. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. *TMPRSS2* and
  COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020; 10:779–
  782.
- 39. Walker RF, Zakai NA, MacLehose RF, Cowan LT, Adam TJ, Alonso A, Lutsey PL.
  Association of Testosterone Therapy With Risk of Venous Thromboembolism Among
  Men With and Without Hypogonadism. JAMA Intern Med. 2020; 180:190–197.
- 40. Liu H, Wei P, Kappler JW, Marrack P, Zhang G. SARS-CoV-2 Variants of Concern and
  Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. Front
  Immunol. 2022 Jan 27; 13:825256. doi: 10.3389/fimmu.2022.825256. PMID: 35154144;
  PMCID: PMC8828474.
- 559

It is made available under a CC-BY 4.0 International license .

# 560 Supporting Information:

561	1.	Supplement 1: Patient selection and distribution of the patient for this cross-sectional
562		study
563	2.	Supplement 2: Difference in daily oxygen support, daily positive cases and daily test
564		variability in three waves
565		
566		
567		
568		
569		
570		
571		
572		
573		
574		
575		
576		
577		
578		
579		
580		
581		

582			
583			
584			
585			
586			
587			
588			
589			
590			
591			
592			
593			
594			
595			
596			
597			
598			
599			
600			
601			
602			
603			



Figure 1

# Figure 1: Symptoms clusters in COVID-19

a. According to general clusters of symptoms, We found three clusters of symptoms among the admitted patients with COVID-19: 1. Fever, cough, and respiratory distress. 2. Anosmia, headache, and anorexia, 3. Sore throat and running nose. b. In the first wave, we found three clusters 1. Respiratory distress and cough, 2. Anosmia anorexia, and 3. Running nose and sore throat. c. In the second wave, we found a cluster headache, running nose, sore throat, and hoarseness of voice. d. In the third wave, we found three clusters 1.

(cov-COVID-19, Fvr-Fever, Cgh-cough, Rnn-Running nose, Rsd-Respiratory distress, Srt-Sore throat, Hrv-Hoarseness of voice, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, Lth-Lethargy, Ach-Body ache)

# Figure 1 legends

Anorexia and anosmia 2 Fever and cough and 3 headache, diarrhea, and vomiting. medRxiv preprint doi: https://doi.org/10.1101/2022.12.14.22283379; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

We did the network analysis with tidy verse and q graph using R (v4.1.1).







b

Daily during 3 waves of Covid-19



С

# Figure 2

# Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in three surges

- a. Test positivity-The first surge remained longer and the second surge was narrowest. The daily number of positive cases was high in the second and third surge.
- Daily admission-Number of daily admissions was highest in the initial part of the first wave and third wave
- c. Daily death-Number of daily deaths was highest in the initial part of the first wave and third wave

(The first, second, and third waves extend from April 2020 to January 2020, February 2021 to May 2021, and June 2021 to September 2021, respectively)

medRxiv preprint doi: https://doi.org/10.1101/2022.12.14.22283379; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

# Figure 2 legends



Figure 3

# Figure 3: Symptom cluster in post COVID-state

There were five cluster of symptoms in the post-COVID state, 1-diarrhea and vomiting, 2-fatigue and anorexia, 3-memory loss and insomnia, 4-persistent cough and sputum, 5-sore throat and respiratory distress.

We did the network analysis with tidy verse and q graph using R (v4.1.1). (cov-COVID-19, Ftg-Fatigue, Ptc- persistent cough, Spt-sputum, Rsd-Respiratory distress, Srt-Sore throat, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, NHT: new onset hypertension, NDM: new onset diabetes, Mmd-Memory disturbance

medRxiv preprint doi: https://doi.org/10.1101/2022.12.14.22283379; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

# Figure 3 Legends